Immunic, Inc. reported that its pivotal Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium for relapsing multiple sclerosis remain on schedule, with top-line data expected in December 2026. The company is also initiating a Phase 3 PROTECT-MS trial for progressive multiple sclerosis, with first patient enrollment anticipated in the first half of 2027. Positive results could lead to a New Drug Application submission in mid-2027 and potential approval in 2028. Immunic is strengthening its leadership team to support regulatory and commercial readiness as it transitions toward potential market launch.
Immunic, Inc.'s recent corporate update coincides with a health sector where 93 of 150 US stocks rose today. For readers following health stocks, here is Pluang's market snapshot as of Nov 13, 2026 18:41 WIB: FLNA (Cassava Sciences Inc) gained 7.05% to USD 0.48 with 87% buy activity, HRTX (Heron Therapeutics Inc) rose 5.80% to USD 0.35 with a balanced order split, and MMED (MiniMed Group Inc.) fell 4.90% to USD 17.00 with a typical hold time of 19 days.
KeyBanc lowered its price target for YETI Holdings to $49, suggesting a 27.94% upside from the current $38.30 stock price. This follows YETI's reduction of its full-year adjusted sales growth forecast to about 6% from the previous 7-8%, citing consum...
Bernstein SocGen Group has reduced its price target for Applied Materials to $600, even though the company reported higher sales and profits in Q4 2026 driven by strong demand for semiconductor services, especially AI chips. Applied Materials posted ...
Boralex Inc. announced a private placement of $600 million Canadian dollars in green bonds, split into two series maturing in 2031 and 2036 with interest rates of 4.503% and 5.173%, respectively. This marks Boralex's first issuance of green corporate...
Boralex Inc. announced the issuance of C$600 million in green bonds, split into two series with maturities in 2031 and 2036, bearing interest rates of 4.503% and 5.173% respectively. This marks Boralex's first green-labelled corporate securities offe...
Investec Bank Plc, acting as an exempt principal trader and advisor to DBAY Advisors Limited, disclosed the sale of 25,000 ordinary shares of Logistics Development Group Plc on November 12, 2026. The shares were sold at a price of 23 per unit. There ...
